207 related articles for article (PubMed ID: 29796172)
1. Oncodriver inhibition and CD4
Rosemblit C; Datta J; Lowenfeld L; Xu S; Basu A; Kodumudi K; Wiener D; Czerniecki BJ
Oncotarget; 2018 May; 9(33):23058-23077. PubMed ID: 29796172
[TBL] [Abstract][Full Text] [Related]
2. Progressive loss of anti-HER2 CD4
Datta J; Rosemblit C; Berk E; Showalter L; Namjoshi P; Mick R; Lee KP; Brod AM; Yang RL; Kelz RR; Fitzpatrick E; Hoyt C; Feldman MD; Zhang PJ; Xu S; Koski GK; Czerniecki BJ
Oncoimmunology; 2015 Oct; 4(10):e1022301. PubMed ID: 26451293
[TBL] [Abstract][Full Text] [Related]
3. Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.
Datta J; Berk E; Xu S; Fitzpatrick E; Rosemblit C; Lowenfeld L; Goodman N; Lewis DA; Zhang PJ; Fisher C; Roses RE; DeMichele A; Czerniecki BJ
Breast Cancer Res; 2015 May; 17(1):71. PubMed ID: 25997452
[TBL] [Abstract][Full Text] [Related]
4. CD4(+) T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8(+) T-cell Targeting of HER2/neu-Expressing Cancers.
Datta J; Xu S; Rosemblit C; Smith JB; Cintolo JA; Powell DJ; Czerniecki BJ
Cancer Immunol Res; 2015 May; 3(5):455-63. PubMed ID: 25791067
[TBL] [Abstract][Full Text] [Related]
5. Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer: Role for Immune Monitoring.
Datta J; Fracol M; McMillan MT; Berk E; Xu S; Goodman N; Lewis DA; DeMichele A; Czerniecki BJ
JAMA Oncol; 2016 Feb; 2(2):242-6. PubMed ID: 26719971
[TBL] [Abstract][Full Text] [Related]
6. T-helper 1-type cytokines induce apoptosis and loss of HER-family oncodriver expression in murine and human breast cancer cells.
Namjoshi P; Showalter L; Czerniecki BJ; Koski GK
Oncotarget; 2019 Oct; 10(57):6006-6020. PubMed ID: 31666931
[TBL] [Abstract][Full Text] [Related]
7. Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway.
Jia Y; Kodumudi KN; Ramamoorthi G; Basu A; Snyder C; Wiener D; Pilon-Thomas S; Grover P; Zhang H; Greene MI; Mo Q; Tong Z; Chen YZ; Costa RLB; Han H; Lee C; Soliman H; Conejo-Garcia JR; Koski G; Czerniecki BJ
Mol Ther; 2021 Apr; 29(4):1541-1556. PubMed ID: 33412308
[TBL] [Abstract][Full Text] [Related]
8. Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention.
Nocera NF; Lee MC; De La Cruz LM; Rosemblit C; Czerniecki BJ
Front Pharmacol; 2016; 7():356. PubMed ID: 27766079
[TBL] [Abstract][Full Text] [Related]
9. HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.
Canonici A; Ivers L; Conlon NT; Pedersen K; Gaynor N; Browne BC; O'Brien NA; Gullo G; Collins DM; O'Donovan N; Crown J
Invest New Drugs; 2019 Jun; 37(3):441-451. PubMed ID: 30062574
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib Combined with Th1 Cytokines Potentiates Apoptosis in Human Breast Cancer Cells and Suppresses Tumor Growth in a Murine Model of HER-2
Ghimirey N; Steele C; Czerniecki BJ; Koski GK; Showalter LE
Int J Breast Cancer; 2021; 2021():8818393. PubMed ID: 33936816
[TBL] [Abstract][Full Text] [Related]
11. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
12. Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model.
Yamashita-Kashima Y; Shu S; Yorozu K; Moriya Y; Harada N
Oncol Lett; 2017 Oct; 14(4):4197-4205. PubMed ID: 28959366
[TBL] [Abstract][Full Text] [Related]
13. Prolactin activates Stat1 but does not antagonize Stat1 activation and growth inhibition by type I interferons in human breast cancer cells.
Schaber JD; Fang H; Xu J; Grimley PM; Rui H
Cancer Res; 1998 May; 58(9):1914-9. PubMed ID: 9581833
[TBL] [Abstract][Full Text] [Related]
14. Loss of Anti-HER-3 CD4+ T-Helper Type 1 Immunity Occurs in Breast Tumorigenesis and is Negatively Associated with Outcomes.
Fracol M; Datta J; Lowenfeld L; Xu S; Zhang PJ; Fisher CS; Czerniecki BJ
Ann Surg Oncol; 2017 Feb; 24(2):407-417. PubMed ID: 27663569
[TBL] [Abstract][Full Text] [Related]
15. CD4 T-cell immune stimulation of HER2 + breast cancer cells alters response to trastuzumab in vitro.
Song PN; Mansur A; Dugger KJ; Davis TR; Howard G; Yankeelov TE; Sorace AG
Cancer Cell Int; 2020 Nov; 20(1):544. PubMed ID: 33292267
[TBL] [Abstract][Full Text] [Related]
16. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
Diermeier-Daucher S; Breindl S; Buchholz S; Ortmann O; Brockhoff G
Cytometry A; 2011 Sep; 79(9):684-93. PubMed ID: 21786419
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-4 supports interleukin-12-induced proliferation and interferon-gamma secretion in human activated lymphoblasts and T helper type 1 cells.
Kriegel MA; Tretter T; Blank N; Schiller M; Gabler C; Winkler S; Kalden JR; Lorenz HM
Immunology; 2006 Sep; 119(1):43-53. PubMed ID: 16762027
[TBL] [Abstract][Full Text] [Related]
18. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.
Yamashita-Kashima Y; Shu S; Harada N; Fujimoto-Ouchi K
Oncol Rep; 2013 Sep; 30(3):1087-93. PubMed ID: 23783223
[TBL] [Abstract][Full Text] [Related]
19. Cytokine-stimulated GTP cyclohydrolase I expression in endothelial cells requires coordinated activation of nuclear factor-kappaB and Stat1/Stat3.
Huang A; Zhang YY; Chen K; Hatakeyama K; Keaney JF
Circ Res; 2005 Feb; 96(2):164-71. PubMed ID: 15604419
[TBL] [Abstract][Full Text] [Related]
20. The role of STAT1/IRF-1 on synergistic ROS production and loss of mitochondrial transmembrane potential during hepatic cell death induced by LPS/d-GalN.
Lee HJ; Oh YK; Rhee M; Lim JY; Hwang JY; Park YS; Kwon Y; Choi KH; Jo I; Park SI; Gao B; Kim WH
J Mol Biol; 2007 Jun; 369(4):967-84. PubMed ID: 17475277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
